Antigen News and Research

RSS

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

New research, presented this morning at the 54th Annual Meeting of the American Society of Hematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that may help researchers identify young children who are more susceptible to eBL.

12 Dec 2012

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

11 Dec 2012

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate).

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Tenofovir DF safe and effective in treating adolescents with HBV

A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants.

6 Dec 2012

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

Beckman Coulter Life Sciences is expanding their flow cytometry portfolio with the addition of 14 new human monoclonal antibodies from Trillium Diagnostics LLC.

From Beckman Coulter Life Sciences - Flow Cytometry 30 Nov 2012

Dutasteride delays PSA progression

The 5α-reductase inhibitor, dutasteride, delays the clinical progression of prostate cancer in patients with prostate-specific antigen levels that have failed to reduce adequately following radical therapy for localized disease, report researchers.

28 Nov 2012

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

28 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Single dose of Medicago's vaccine could offer cross-protection against flu

Researchers recently found that a single dose of a vaccine being developed by Medicago, Inc., a publicly traded biopharmaceutical company, could protect against not only the avian influenza (H5N1) strain it was designed for, but also another H5N1 strain and a strain of a different flu subtype, called H2N2.

22 Nov 2012

Strep detection tests may miss sore throat-causing bacterial strains

Rapid streptococcal antigen detection tests, which are widely used to detect non-group A Lancefield beta-hemolytic streptococci in many developed countries, may be missing clinically important streptococci, say researchers.

19 Nov 2012

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stopping its attack on myelin and halt a model of relapsing remitting multiple sclerosis (MS) in mice, according to new Northwestern Medicine research.

19 Nov 2012

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.

18 Nov 2012

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

Antigen News and Research

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

New hope for leukemia patients

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

Tenofovir DF safe and effective in treating adolescents with HBV

14 new human monoclonal antibodies introduced by Beckman Coulter Life Sciences

Dutasteride delays PSA progression

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

mRNA vaccines offer protection against influenza A virus infections in various animal models

Single dose of Medicago's vaccine could offer cross-protection against flu

Strep detection tests may miss sore throat-causing bacterial strains

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

NIH-funded scientists develop new treatment to combat autoimmune disorders in mouse model

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics